arGEN-X Announces Collaboration with Bayer to Discover and Develop Therapeutic Antibody Candidates

May 28, 2014

BREDA, The Netherlands, May 28, 2014 /PRNewswire/ –

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing
differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune
diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer),
leveraging arGEN-X’s SIMPLE Antibody(TM) technology for the discovery and development of
therapeutic antibodies. The collaboration centers on a novel approach to addressing
complex targets across multiple therapeutic areas that are often intractable by existing
antibody platforms.

“We are delighted that Bayer, with its long-standing expertise in drug development,
will make use of the SIMPLE Antibody(TM) platform. As a company, we are dedicated to
forming elite partnerships and feel that with this new collaboration, we have firmly
established SIMPLE Antibody(TM) as an innovative solution to reaching intractable targets
and tackling unmet needs in antibody discovery,” said Tim Van Hauwermeiren, Chief
Executive Officer of arGEN-X. “We are confident that by building on our proprietary
capabilities in DNA immunization and the unique immune system of the llama, we have
developed a novel platform that will create potential new product opportunities.”

With this collaboration, arGEN-X will apply its SIMPLE Antibody(TM) technology to
multiple targets submitted by Bayer. The parties will work together to validate human
antibody leads in disease-relevant models, with Bayer being responsible for further
preclinical and clinical development and commercialization of therapeutic antibody
products. Under the terms of the Agreement, Bayer will pay arGEN-X an upfront technology
access fee, research support and technical success-based milestones. Bayer will also pay
clinical, regulatory and product sales-based milestones as antibody programs progress
through clinical development and registration.

“We look forward to collaborating with arGEN-X and exploring the potential of SIMPLE
Antibody(TM) technology to complement Bayer’s efforts in the discovery and development of
first-in-class therapeutic antibodies,” said Dr. Harald Dinter, Head of Global Biologics
at Bayer Pharma AG.

About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and
developing differentiated therapeutic antibodies for the treatment of cancer and severe
autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody
candidates using its SIMPLE Antibody(TM) discovery platform. SIMPLE Antibody(TM) has a
particular strength in addressing novel, complex disease targets that are difficult to
access using established antibody technology platforms. Fc engineering technologies -
NHance(R), ABDEG(TM) and POTELLIGENT(R) – further enhance the therapeutic properties of
SIMPLE Antibody(TM) leads in terms of their residence time in the body, their ability to
clear disease targets or pathogenic antibodies and their cell killing potency through
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged
its suite of antibody technologies in forging strategic collaborations with pharmaceutical
and biotechnology companies to provide new approaches to diseases with unmet medical


For further information, please contact:

        Tim Van Hauwermeiren
        Chief Executive Officer

        Debbie Allen
        VP Business Development


        Mark Swallow/David Dible
        Citigate Dewe Rogerson

        Beth DelGiacco
        Stern Investor Relations


Source: PR Newswire

comments powered by Disqus